Pricing Log in Create free account

Insight Molecular Diagnostics Inc. (IMDX) vs Exagen Inc. (XGN)

Insight Molecular Diagnostics Inc. and Exagen Inc. are both Diagnostics & Research companies. Exagen Inc. is the larger, with a market value of $207.4M against $100.1M — 2.1× the size. Exagen Inc. grew revenue faster over the last twelve months: 20.8% against −60.8%. Exagen Inc. has the higher net margin (−26.6% vs −2,955.6%) and the lower return on invested capital (−68.3% vs 0.00%). Across the 17 metrics below, Exagen Inc. leads on 11 and Insight Molecular Diagnostics Inc. on 6.

Valuation

Metric IMDX XGN Diagnostics & Research median
P/E n/m n/m 35.56
P/S 66.24 2.60 4.37
P/B n/m 15.13 3.06
Price to free cash flow n/m n/m 35.76
EV/EBITDA n/m n/m 24.35
EV/Sales 55.72 2.60 5.51
Earnings yield (49.50%) (10.59%) (1.89%)
Free cash flow yield (28.02%) (4.10%) (0.15%)

Profitability

Metric IMDX XGN Diagnostics & Research median
Gross margin 48.32% 58.64% 50.89%
Operating margin (3,011.86%) (18.58%) (8.57%)
Net margin (2,955.63%) (26.61%) (6.37%)
Free cash flow margin (1,856.23%) (10.66%) 0.00%
Return on equity 488.68% (113.82%) (2.92%)
Return on assets (123.46%) (34.19%) (6.71%)
Return on invested capital 0.00% (68.33%) 0.00%

Growth

Metric IMDX XGN Diagnostics & Research median
Revenue growth (TTM) (60.77%) 20.83% 7.69%
EPS growth (last fiscal year) 64.59% (12.05%) 25.92%
Revenue growth, 5-year CAGR 27.24% 9.66% 7.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IMDX XGN Diagnostics & Research median
Debt to equity (0.04) 2.00 0.11
Current ratio 2.00 3.18 2.02
Net debt to EBITDA (0.67) 0.68 0.70

Dividend

Metric IMDX XGN Diagnostics & Research median
Dividend yield — — 0.66%
Payout ratio — — 0.20

Size

Metric IMDX XGN Diagnostics & Research median
Market cap 100.14m 207.37m 2.16b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack